SCHEMBL21753374

SCHEMBL21753374

CS(=O)(=O)c1cncc(-c2ccc(CCl)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 7/20 0.48
PIK3CD O00329 3/20 0.48
PIK3CA P42336 3/20 0.48
PIK3CB P42338 2/20 0.48
PI4KA P42356 1/20 0.48
PI4KB Q9UBF8 1/20 0.48
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
PIK3C3 Q8NEB9 1/20 0.45
GPR55 Q9Y2T6 2/20 0.43
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CDK5 Q00535 2/20 0.40
CDK5R1 Q15078 2/20 0.40
PTGS2 P35354 4/20 0.39
BRD4 O60885 1/20 0.38
CREBBP Q92793 1/20 0.38
CYP11B2 P19099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21753363 0.84 PTGS2 (0.50) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL17795259 0.80 PIK3CG (0.52) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL29541780 0.80 PIK3CG (0.36) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL17169788 0.80 PIK3CG (0.36) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL5700416 0.78 PIK3CG (0.50) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
Hydrochloric Acid SCHEMBL17161921 0.78 PIK3CG (0.35) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL21753331 0.78 NR1H2 (0.51)
SCHEMBL21753325 0.76 PIK3CG (0.49) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL17806575 0.76 PIK3CG (0.49) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL398570 0.73 ENPP2 (0.50) CYP3A4CYP2C9PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP PIK3CG 3659/4885PIK3CD 4030/4885PIK3CA 3617/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP PIK3CG 3618/4885PIK3CD 3987/4885PIK3CA 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.